Myopericarditis with Significant Left Ventricular Dysfunction Following COVID-19 Vaccination: A Case Report

Area of Science:

• Cardiology
• Vaccinology
• Public Health

Background:

• The safety profile of COVID-19 vaccines is continually evolving.
• Myopericarditis is an identified rare adverse event following COVID-19 vaccination, predominantly in younger demographics.
• Uncertainty exists regarding recovery outcomes in older patients or those with pre-existing cardiac dysfunction.

Observation:

• A case report details a middle-aged male experiencing myopericarditis with significant left ventricular dysfunction post-Pfizer-BioNTech BNT162b2 vaccination.
• The patient presented with symptoms several days after receiving the second vaccine dose.
• Treatment with non-steroidal anti-inflammatory drugs was initiated.

Findings:

• Rapid recovery of ventricular function was observed in the patient.
• Symptomatic resolution occurred within one week of vaccination.
• The patient demonstrated a positive clinical outcome despite initial cardiac dysfunction.

Implications:

• This case suggests that even individuals with moderate cardiac dysfunction may experience favorable recovery after vaccine-induced myopericarditis.
• Findings aim to alleviate public hesitancy towards COVID-19 vaccination due to concerns about rare adverse events.
• Rare adverse effects, such as myopericarditis, should not discourage widespread vaccination efforts crucial for pandemic control.